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1. Underlying principles
While many ART guidelines are available internationally, 
these guidelines have been written to address issues relevant to 
Southern Africa. The following general principles underpinned 
the writing process: 
•	 South Africa is a middle-income country whereas certain 
other countries in the region are low-income countries; 
therefore, affordability was taken into account.
•	 Only treatment and diagnostic options available in Southern 
Africa were included.
•	 We recognised the need to bridge the gap in treatment 
recommendations between public and private sector 
programmes, considering that many patients transition 
between the 2 sectors for treatment.
•	 The guidelines are intended to reflect ‘best practice’ – 
while it is acknowledged that certain recommendations are 
aspirational for poorly resourced settings, the unavailability 
of diagnostic/monitoring tests should not be a barrier to 
providing ART to those in need.
•	 There has been a shift to view treatment as a means of 
HIV prevention. The evidence base for this exists for 
serodiscordant couples; recommendations in this regard 
are included in these guidelines and additional data from 
community studies are awaited.
•	 References for key new recommendations were included to 
address the need for supporting evidence.
2. Goals of therapy
The primary goals of ART are to:
•	 improve quality of life
•	 reduce HIV-related morbidity and mortality 
•	 provide maximal and durable suppression of viral load
•	 restore and/or preserve immune function.
These goals are achieved by completely suppressing viral 
replication for as long as possible using well-tolerated and 
sustainable treatment. With prolonged viral suppression, the 
CD4 lymphocyte count usually increases, which is accompanied 
by partial restoration of pathogen-specific immune function. 
For most patients, this results in a dramatic reduction in the 
risk of HIV-associated morbidity and mortality. It is still unclear 
whether immune function ever returns to full normality. Long-
term cohorts will provide answers, but for now, and for practical 
purposes, clinicians should treat patients who adhere to ART 
with the anticipation of a near-normal life expectancy.
3. Standard of care
Maximally suppressive ART regimens should be used to obtain 
the best results and to prevent resistance. In the region, non-
suppressive regimens such as mono/dual nucleoside reverse 
transcriptase inhibitor (NRTI) therapies have historically 
been used. The initiation of such therapies is now strongly 
discouraged. However, non-suppressive regimens have a role 
in the prevention of mother-to-child transmission (PMTCT) 
and in post-exposure prophylaxis (PEP) for healthcare 
workers following occupational exposure. Furthermore, they 
are probably effective following sexual exposure. For further 
guidance:
Southern African HIV Clinicians Society. Post-exposure prophylaxis. 
Southern African Journal of HIV Medicine 2008;9:36-45.
These guidelines are intended as an update to those published 
in the Southern African Journal of HIV Medicine in January 
2008. Since the release of the previous guidelines, the scale-
up of antiretroviral therapy (ART) in Southern Africa has 
continued to grow. Cohort studies from the region show 
excellent clinical outcomes; however, ART is still being 
started late (in advanced disease), resulting in relatively 
high early mortality rates. New data on antiretroviral (ARV) 
tolerability in the region and several new ARV drugs have 
become available. Although currently few in number, some 
patients in the region are failing protease inhibitor (PI)-
based second-line regimens. To address this, guidelines on 
third-line (or ‘salvage’) therapy have been expanded.
S Afr J HIV Med 2012;13(3):114-133. DOI:10.7196/SAJHIVMED.862






4.  Classes of ARV agents and 
their mechanisms of action
The most commonly used ARV agents in the region inhibit 1 of 3 key 
HIV enzymes that are required by the virus for intracellular replication 
(Table 1):
•	 reverse transcriptase – essential for completion of the early stages of 
HIV replication
•	 protease – required for the assembly and maturation of fully-
infectious viral progeny
•	 integrase – required for the integration of proviral DNA into the host 
chromosomal DNA.
5.  ARV agents currently 
available in Southern Africa 
(Table 2)
5.1 Notes
Different fixed-dose drug combinations are increasingly being made 
available. The oldest combination is zidovudine (AZT)/lamivudine (3TC), 
but a number of other 2 - 3 fixed-dose combinations are now available in 
Southern Africa. These reduce the burden of multiple pills and improve 
adherence. However, side-effects remain as described in Table 2.
Low-dose ritonavir is used to ‘boost’ the concentration of other 
PIs. It is always used with lopinavir (LPV) (fixed-dose combination) 
and saquinavir (SQV) and is strongly encouraged with other PIs. 
The following PIs are recommended for use: LPV/ritonavir (LPV/r), 
atazanavir/ritonavir (ATV/r) and darunavir/ritonavir (DRV/r). Patients 
receiving older PIs (e.g. SQV and indinavir) should be switched to 
these (consult an expert if the patient’s viral load is not suppressed). We 
recommend against regimens containing dual ritonavir-boosted PIs, as 
there is no evidence for superior efficacy1 and significant side-effects 
are likely.
Combinations to be avoided include: (i) AZT plus d4T (antagonism); 
(ii) tenofovir (TDF) plus didanosine (ddI) (associated with poorer 
virological and immunological responses and increased toxicity); and 
(iii) D4T plus ddI (associated with a very high risk for mitochondrial 
toxicities such as lactic acidosis and peripheral neuropathy). 
6. Indications for starting ART
Indications for ART initiation are summarised in Table 3. ART initiation 
is never an emergency, unless used for PEP or PMTCT. However, 
patients with profound immunosuppression are at significant risk of 
opportunistic illnesses, and should be assessed rapidly and initiated on 
ART as soon as adherence is assured. The following investigations are 
recommended prior to initiating ART:
•	 alanine transaminase (ALT)
•	 full blood count (FBC)
•	 serum creatinine and calculate creatinine clearance: avoid TDF if 
creatinine clearance is <50 ml/min; other NRTIs, except abacavir 
(ABC), require dose adjustment if creatinine clearance is <50 ml/min 
(see the modified Cockgraft-Gault equation – Table 9)
•	 urinalysis for proteinuria
•	 hepatitis B surface antigen
•	 CD4 count.
Where feasible, a serum or plasma cryptococcal antigen test should 
be performed in patients starting ART with a CD4 count <100 cells/
μl, to screen for early cryptococcal disease and to initiate pre-emptive 
treatment if needed. In addition, a baseline HIV viral load should be 
performed where feasible.
ART should be deferred until patients are prepared to commit to 
long-term treatment and maintaining good treatment adherence. 
However, efforts should be made to avoid lengthy indecision that may 
result in avoidable clinical deterioration and death.
Table 1. Classes of ARV agents
Class Abbreviation Mechanism of action Specific action
Nucleoside and nucleotide reverse 
transcriptase inhibitors
NRTIs and NtRTIs Reverse
transcriptase
inhibition
Nucleic acid analogues that mimic 
the normal building blocks of DNA, 







Small compounds shaped to fit into the 
genomic HIV binding site of reverse 
transcriptase and directly inhibit its action
Protease inhibitors PIs Protease
inhibition
Inhibit the final maturation stages of HIV 
replication, resulting in the formation of 
non-infective viral particles
Entry inhibitors* - Entry inhibition Bind to viral gp41 or host cell CD4 or 
chemokine (CCR5) receptors
Integrase inhibitors
(also termed integrase strand 
transfer inhibitors)
InSTIs Inhibit viral integration Prevent the transfer of proviral DNA 
strands into the host chromosomal DNA
 * Not yet available in Southern Africa. 
ARV = antiretroviral; DNA = deoxyribonucleic acid; RNA = ribonucleic acid. 







Table 2. Dose and common adverse drug reactions of ARV agents available in Southern Africa
Generic name
Class of 
drug* Recommended dosage Common or severe adverse drug reactions†
Zidovudine (AZT) NRTI 300 mg 12-hourly Bone marrow suppression, gastro-intestinal (GI) upset, 
headache, myopathy, hyperlactataemia/steatohepatitis 
(medium potential), lipo-atrophy
Didanosine (ddI) NRTI 400 mg daily (250 mg daily if <60 kg) 
taken on an empty stomach
(enteric coated formulation preferred)
Peripheral neuropathy, pancreatitis, nausea, diarrhoea, 
hyperlactataemia/steatohepatitis (high potential)
Lamivudine (3TC) NRTI 150 mg 12-hourly or 300 mg daily Anaemia (pure red cell aplasia) (rare), hyperlactataemia/
steatohepatitis (very low potential)
Stavudine (D4T) NRTI 30 mg 12-hourly 
Note: higher doses for >60 kg no 
longer recommended due to toxicity
Peripheral neuropathy, lipo-atrophy, hyperlactataemia/
steatohepatitis (high potential), pancreatitis, HIV-
associated neuromuscular weakness syndrome (HANWS) 
(rare), dyslipidaemia
Abacavir (ABC) NRTI 300 mg 12-hourly or 600 mg daily Hypersensitivity reaction, hyperlactataemia/
steatohepatitis (very low potential)
Tenofovir (TDF) NtRTI 300 mg daily Renal failure, tubular wasting syndrome, reduced bone 
mineral density, hyperlactataemia/steatohepatitis (very low 
potential)
Emtricitabine (FTC) NRTI 200 mg daily Palmar hyperpigmentation, hyperlactataemia/
steatohepatitis (very low potential)
Nevirapine (NVP) NNRTI 200 mg daily for 14 days then 200 mg 
12-hourly 
Rash, hepatitis 
Efavirenz (EFV) NNRTI 600 mg at night Central nervous system symptoms (vivid dreams, problems 
with concentration, confusion, mood disturbance, 
psychosis), rash, hepatitis, gynaecomastia
Etravirine (ETV) NNRTI 200 mg 12-hourly Rash, hepatitis
Indinavir (IDV)
(rarely used)
PI 800 mg 12-hourly with 100 mg 
ritonavir 12-hourly
No food restrictions
Maintain high fluid intake
Kidney stones, unconjugated hyperbilirubinaemia (visible 
jaundice in minority of patients), GI disturbances, hair loss, 
hyperglycaemia, headache, dyslipidaemia
Atazanavir (ATV) PI 400 mg daily (only if ART-naive) or 
300 mg with ritonavir 100 mg daily 
(preferable)
With TDF 300/100 mg daily and with 
EFV 400/100 mg daily
Unconjugated hyperbilirubinaemia (visible jaundice in 




Boosted PI 400/100 mg 12-hourly or 800/200 mg 
daily (only if PI-naive). 
GI upset, dyslipidaemia, hepatitis
Darunavir (DRV) PI 600 mg 12-hourly with 100 mg 
ritonavir 12-hourly or 800/100 mg 
daily (only if PI-naive)
GI upset, rash, dyslipidaemia, hepatitis
Contains sulphonamide moiety (use with caution in 
patients with sulpha allergy)
Saquinavir 
(SQV) (hard gel 
formulation, rarely 
used)
PI 1 000 mg with 100 mg ritonavir 
12-hourly, or 1 600 mg with 100 mg 
ritonavir daily (only if PI-naive) 
Take with a fatty meal, or up to 2 
hours after meal
GI disturbance (mild), hepatitis, hyperglycaemia, 
dyslipidaemia
Raltegravir (RAL) InSTI 400 mg 12-hourly Rash (rare), headache, GI upset
*All protease inhibitors (PIs) may be associated with cardiac conduction abnormalities (especially PR prolongation). This seldom results in clinically significant effects, but caution 
should be taken when co-prescribing other drugs that cause delayed cardiac conduction, such as macrolides.
†Life-threatening reactions are indicated in bold.
NRTI = nucleoside reverse transcriptase inhibitor; NtRTI = nucleotide reverse transcriptase inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; 
InSTI = integrase inhibitor (integrase strand transfer inhibitor).






6.1 Rationale for these guidelines
6.1.1 CD4 threshold
A randomised trial in Haiti demonstrated reduced mortality and 
incident tuberculosis (TB) in patients starting ART at a CD4 threshold 
<350 cells/µl (compared with patients waiting to start therapy at <200 
cells/μl).2 Some observational data suggest that reduced morbidity 
and mortality are associated with starting ART even earlier (at CD4 
thresholds of 500 cells/μl or above that).3-6 However, these data are 
derived from retrospective studies with methodological issues and 
probable residual confounding. If there is benefit to patients starting 
ART at CD4 counts >350 cells/μl, the benefit is likely to be small, 
since HIV-related events at high CD4 counts are rare. A randomised 
controlled trial (RCT) (HPTN052) showed reduced morbidity but not 
mortality associated with starting ART at a CD4 count of 350 - 550 
cells/µl (compared with <250 cells/μl).7 However, again, the absolute 
benefits were small. Definitive evidence regarding earlier ART initiation 
is awaited from an ongoing RCT, the START study (http://clinicaltrials.
gov/ct2/show/NCT00867048).
 
6.1.2 Treating WHO stage 3
Many observational studies have shown that TB (the most common 
World Health Organization (WHO) stage 3 condition associated with 
HIV) accelerates HIV disease progression and increases mortality.8 We 
advise that an episode of HIV-associated TB (i.e. TB diagnosed at the 
time of seropositive HIV test) is a sufficient criterion for ART, but not 
remote episodes of TB when the patient’s HIV status was unknown. 
6.1.3 Serodiscordant couples
The HPTN052 trial showed that treating the HIV-infected partner 
in a serodiscordant relationship with ART was associated with a 96% 
reduction in transmission risk to the uninfected partner.7
6.2 Starting ART in patients with TB
Decisions regarding the timing of ART in patients with TB should be 
made on the basis of the CD4 count:
•	 CD4 count ≤50 cells/µl: ART should be regarded as urgent, and 
the aim should be to start therapy after 2 weeks of TB treatment. 
Three RCTs9-11 have demonstrated that this approach reduces AIDS 
progression and mortality. It is advised to commence ART after it 
is clear that the patient’s TB symptoms are improving and that TB 
therapy is tolerated.
•	 CD4 count >50 cells/µl: ART should be delayed until after the 
intensive phase of TB treatment (2 months) unless the patient has 
other serious HIV-related conditions (e.g. Kaposi’s sarcoma or HIV 
encephalopathy). The longer delay before commencing ART in this 
group is expected to reduce the risk of shared toxicity (as the patient 
will then be receiving fewer TB drugs) and to reduce the risk of the 
immune reconstitution inflammatory syndrome (IRIS) (section 15). 
The RCTs did not show a higher risk of AIDS progression/mortality 
in this group when ART initiation was delayed until 2 months after 
starting TB treatment.9-11
•	 There are important drug interactions and shared side-effects when 
ART is co-administered with TB therapy (section 13.1).
Table 3. Indications for ART*
Clinical diagnoses (irrespective of CD4 count)
WHO clinical stage 3 and 4† ART recommended 







Malignancies (excluding localised malignancies)
Hepatitis B¶
Hepatitis C




<350 cells/µl ART recommended
>350 cells/µl Defer ART 
HIV-infected partner in serodiscordant relationship
Regardless of CD4 count or clinical diagnoses Offer ART and discuss safe sex (discussion must involve both 
partners)
*Note that EITHER listed clinical diagnoses OR CD4 strata would be an indication for ART.
†See Appendix.
‡Specialist input required. Note that this list is not exhaustive – any other severe HIV-related disorder should be considered an indication for ART. 
§Specialist input required. Other disorders that may benefit from improvement in immune function should also be considered as an indication to start ART. Also, given that untreated HIV appears to be a 
risk factor for vascular disease, patients with symptomatic vascular disease or diabetes mellitus can be considered for earlier ART.
¶Hepatitis B that qualifies for specific anti-hepatitis B therapy (see section 13.5 for criteria and recommended ART regimens).







•	 When ART is commenced, patients should be warned that TB 
symptoms or signs may temporarily worsen and new features may 
occur in the first 3 months as a result of TB-IRIS.
•	 Unless contra-indicated, cotrimoxazole prophylaxis should be 
initiated in patients with HIV-associated TB.
•	 Patients with TB meningitis (TBM) starting ART immediately or 
at 2 months following diagnosis were shown to have similar high 
mortality, with more complications in the former.12 We recommend 
starting ART 2 - 8 weeks after TBM diagnosis. 
6.3 Starting ART in patients with other 
opportunistic diseases/infections
For patients with cryptococcal meningitis (CM), the optimal time to 
start ART is currently unclear. The high risk of mortality prior to ART 
and the mortality risk associated with intracranial cryptococcal IRIS 
need to be balanced, and published studies have shown conflicting 
results.13,14 The Cryptococcal Optimal ART Timing (COAT) trial was 
recently stopped early by the Data and Safety Monitoring Board because 
of excess mortality in patients who started ART in hospital 1 - 2 weeks 
after CM diagnosis compared with those starting 5 - 6 weeks after 
diagnosis. The final results of this trial are awaited. In the interim, we 
recommend starting ART around 4 weeks after antifungal treatment 
(preferably amphotericin B-based) is started.
In patients with other infections (e.g. pneumocystis pneumonia 
or bacterial pneumonia) and who have a CD4 count <200 cells/
μl, clinicians should aim to start ART within 2 weeks of starting 
treatment for that infection. In patients with severe Kaposi’s sarcoma 
and lymphoma, ART counselling should be expedited and ART should 
be started as soon as possible. 
Refer to supplementary material: ‘Starting ART in hospital’ and ‘High-
risk patients’.
6.4 Patient readiness for ART
Patient readiness for therapy is as important as the medical indications 
for commencing therapy.
•	 The patient must demonstrate insight and must have established the 
ability to attend reliably. 
•	 Conventionally, ART is not started at the first visit. Usually, 2 - 3 
visits staggered closely together are required before ART is started, 
to accommodate counselling. Prolonged delays in starting ART 
should be avoided. ART should be delayed only if concerns about 
adherence are severe enough to outweigh the risk of HIV disease 
progression.
•	 The patient should be provided with information on the following:
•	 ART is life-long therapy
•	 the importance of 100% adherence
•	 ART side-effects and what to do and who to contact if serious 
side-effects occur.
•	 Active depression or substance abuse should be dealt with.
•	 A personal treatment plan should be formulated for each patient, 
specifying drug storage, strategies for missed doses and how to 
integrate taking medication into daily routine. The patient must be 
made aware of scheduling in terms of clinical follow-up. 
•	 Disclosure of HIV status (to a partner and/or other household 
members) should be strongly encouraged. This has been shown to 
be an important determinant of treatment adherence and assists in 
the provision of patient-directed support. Disclosure also identifies 
exposed contacts for screening and support. This issue needs to be 
handled sensitively in situations where disclosure may have harmful 
consequences, particularly for women.
•	 The patient should be encouraged to join a support group and/
or identify a treatment ‘buddy’. However, neither disclosure nor 
support group participation are prerequisites for good adherence in 
all patients.
•	 Clinicians should ensure that they have the contact details of each 
patient and their treatment ‘buddy’.
•	 Counselling should cover safe-sex practices and address issues 
related to reproductive health (i.e. family planning, contraception, 
condom use, pregnancy and PMTCT).
Refer to supplementary material: ‘Common misconceptions 
regarding ART’ and ‘Adherence interventions’.
6.5 ART in primary infection
There is insufficient evidence to recommend ART for primary infection. 
There are compelling reasons to defer therapy, including lack of proven 
efficacy, drug toxicity, and the potential for drug resistance. Patients with 
severe primary infection progress more rapidly, which is an indication 
for careful follow-up. ART in primary infection should be considered in 
a properly conducted research study, or in the presence of very severe 
symptoms (e.g. meningo-encephalitis), which are rare. Consultation 
with an expert treater is advised. 
7.  Initial ARV regimens for the 
previously untreated patient
In accordance with international recommendations, we recommend the 
use of a non-nucleoside reverse transcriptase inhibitor (NNRTI) and 2 
NRTIs (a safe dual NRTI combination) as the first-line ART regimen. 
In comparison with PIs, NNRTIs are better tolerated in the long term 
and are at least as potent when combined with an appropriate dual 
NRTI combination.15 We do not recommend PI or integrase inhibitor 
(integrase strand transfer inhibitor (InSTI)) use in first-line therapy, 
unless dictated by intolerance or NNRTI contra-indications.
Either NVP or efavirenz (EFV) may be selected as the NNRTI. EFV 
is the preferred NNRTI. NVP should be selected for women in the first 
trimester of pregnancy or those who intend to fall pregnant (section 
13.2). Owing to its neuropsychiatric side-effects, EFV should be 
avoided in those with active psychiatric illness, shift workers and those 
operating heavy machinery or vehicles. NVP should be avoided in 
women with a CD4 count >250 cells/μl and men with a CD4 count >400 
cells/μl initiating ART for the first time, because of the increased risk 
of rash-associated hepatitis. It should be noted, however, that this side-
effect can occur at any CD4 count. Clinicians should consider avoiding 
NVP in patients who may encounter difficulties getting rapid medical 
attention should rash or hepatitis symptoms occur. NVP should also 
be avoided in patients with pre-existent liver disease. When both 
NVP and EFV are contra-indicated, raltegravir (RAL) or a PI could be 
substituted. Any patient starting an NNRTI should be told to report a 
rash, jaundice or symptoms of hepatitis immediately.
Any of the following 2-drug NRTI combinations are recommended 
for use with the NNRTI: 
•	 3TC plus TDF, AZT or ABC
•	 emtricitabine (FTC) – a cytidine analogue very similar to 3TC – 
that is combined with TDF in a fixed-dose combination or with the 
addition of EFV as a triple-drug combination pill.
TDF is the favoured NRTI to use with 3TC (or FTC). Selection 
will depend on affordability and co-morbidity (e.g. patients with 






a creatinine clearance <50 ml/min should not start TDF). If TDF 
is unavailable or contra-indicated, AZT should be used, provided 
that haemoglobin (Hb) is >10 g/dl. A large clinical trial comparing 
ABC- v. TDF-containing first-line regimens showed lower rates of 
virological suppression with ABC in patients with a baseline viral 
load >100 000 copies/ml.16 Similar findings were demonstrated in a 
second study,17 but not confirmed in another.18 ABC is more costly 
and unavailable in most public sector programmes and has been 
associated with an increased risk of myocardial infarction (MI) in 
some, but not all, cohort studies.19,20 The association with MI was 
not confirmed in a meta-analysis of RCTs.21 Nevertheless, caution 
is recommended when considering ABC for patients at significant 
risk of ischaemic heart disease or with established ischaemic heart 
disease. ABC is an option to consider in chronic renal failure where 
TDF and AZT (because of anaemia) cannot be used.
D4T is a cheaper option than TDF, AZT and ABC, but it is 
considerably more toxic. Most public sector programmes in Southern 
Africa have discontinued D4T in first-line ART. Nonetheless, there is 
still a role for D4T in selected patients, when it is used in the short term 
in patients with contra-indications to other NRTIs. A common example 
is a patient with renal dysfunction and anaemia at baseline who could 
be started on D4T for 3 - 6 months and then switched to AZT or TDF 
depending on resolution of the anaemia and/or renal dysfunction. In 
addition, if there is a need for concomitant nephrotoxic medications, 
e.g. aminoglycosides to treat multidrug resistant (MDR)-TB, D4T (or 
AZT or ABC) is preferable to TDF during the period of exposure to the 
other nephrotoxic medication. Patients usually tolerate short-term D4T 
well. Severe D4T side-effects, such as hyperlactataemia, lipo-atrophy 
and other mitochondrial toxicity, typically occur after 4 - 6 months, 
although peripheral neuropathy can develop earlier.
We favour regimens that include fixed-dose combinations and allow 
once-daily dosing (refer to Table 2 for doses and common side-effects).
8.  Laboratory monitoring for 
ART efficacy
8.1 Viral loads 
Viral loads should be performed:
•	 at baseline (before commencing ART, where possible)
•	 at 3 months after the commencement of ART (This early viral load 
is desirable to detect adherence problems early before resistance 
develops. A small number of patients who start with a very high 
viral load may not be fully suppressed at 3 months despite 100% 
adherence, but such patients would have had a >2 log drop in 
viral load from baseline; therefore, the 3-month result should be 
interpreted in relation to the baseline viral load. All patients who 
have a detectable viral load at 3 months should receive additional 
adherence interventions.)
•	 at 6 months thereafter and then every 6 months (in patients who are 
virologically suppressed (undetectable viral load) for longer than 12 
months and who demonstrate reliable adherence and follow-up, it 
may be acceptable to reduce the frequency of viral load monitoring 
to annually)
•	 if viral load is >50 copies/ml, then repeat measurement in 3 months, 
after an adherence intervention.
8.1.1 Notes
(i) A viral load >50 copies/ml while receiving ART should be an 
indication for urgent action to improve adherence. A subsequent ART 
change must be considered if there is not complete viral suppression 
at the subsequent 3-month follow-up viral load (see section 10 - 
'Indications for changing ART').
(ii) Viral load monitoring is key to the success of ART. Decisions to 
change ART made on the basis of virological failure, rather than on 
clinical or immunologic failure alone, result in better patient outcomes. 
If the viral load is undetectable, then the virus cannot mutate and 
develop resistance. A sustained viral load of <50 copies/ml is associated 
with the most durable virological benefit.
8.2 CD4+ counts
CD4 counts should be performed every 6 months. In patients being 
monitored with viral loads once the CD4 count is >200 cells/μl, provided 
that the viral load is suppressed, routine CD4 testing could be stopped 
as it adds little to management. This is expert opinion rather than 
being evidence-based. However, if virological or clinical failure occurs, 
then a CD4 count should be repeated as it may influence management 
decisions.
9. Defining ART failure
In resource-limited settings where viral loads are unavailable, the WHO 
has devised criteria for defining ART failure on the basis of CD4 count 
responses or clinical disease progression. Studies have shown that 
switching ART regimens using these criteria results in a significant 
proportion of patients switching very late (with progressive accumulation 
of resistant mutations) and switching inappropriately (as the CD4 count 
response may be poor, despite optimal virological suppression).22
9.1 Virological criteria for treatment success
Treatment success is defined by:
•	 a decline in viral load of at least 2 log from pre-treatment levels 3 
months after initiating ART
•	 a decline in viral load to <50 RNA copies/ml within 6 months of 
commencing ART and sustained thereafter.
9.2 Virological criteria for treatment failure
Treatment failure is defined by a confirmed HIV viral load of >1 000 
copies/ml in 2 measurements taken 1 - 3 months apart. Several factors 
can influence the measurement of HIV viral load. The decision to alter 
ART should therefore be based on the results of repeat testing after 1 - 3 
months following intensive adherence counselling. Inadequate patient 
adherence to the prescribed regimen remains the most common reason 
for treatment failure. Other important causes include: prior use of 
single-dose NVP for PMTCT, especially when ART is initiated within 
6 months of the PMTCT dose; drug interactions that decrease ART 
concentrations; and transmitted drug resistance, which is currently 
uncommon in the region (<5%).23
9.3 CD4 response
Typically, the CD4 count increases rapidly in the first month of ART, 
by approximately 75 - 100 cells/μl, with a more gradual rise thereafter 
(50 - 100 cells/μl/year).24 Most, but not all, patients achieve a CD4 
count >500 cells/μl after several years of ART, provided that the viral 
load remains suppressed.25-27 However, CD4 responses are highly 
variable and may fail to increase despite virological suppression, in 
about 10 - 20% of patients.28,29 Such patients have a delayed or absent 
CD4 response to ART despite viral suppression, which is termed an 
‘immunological discordant response to ART’. Certain studies suggest 







that older patients are at higher risk. There is no evidence that such 
patients benefit from a change in ART regimen; therefore, the same 
regimen should be continued. Cotrimoxazole prophylaxis should be 
continued if the CD4 count remains <200 cells/μl and isoniazid (INH) 
prophylaxis should be considered. There is evidence that the prognosis 
of such patients is worse than in those who have a CD4 response, but 
better than that of patients not receiving ART. If such patients are 
clinically unwell, TB or lymphoma should be considered as the cause 
of persistent CD4 lymphopaenia.
CD4 counts may continue to rise or remain stable in the presence 
of incomplete viral suppression (which will result in the emergence 
of drug resistance) until the viral load is high (approximately 10 000 
copies/ml and above).30 
10.  Indications for changing ART
Individual ART drugs may be substituted in the event of toxicity (section 
14), provided that the viral load is suppressed or ART was initiated 
within the preceding 6 months. Changing the first-line ART regimen 
to a second-line regimen is a major step. The drugs used in second-
line regimens are often not as well tolerated and are more expensive, 
usually with limited options for subsequent treatment owing to cost. 
For this reason, clinicians tend to switch to second-line ART after a 
prolonged period of virological failure, which will cause a progressive 
increase in the accumulation of resistant mutations. This reduces the 
efficacy of second-line and subsequent regimens. If the viral load is 
>1 000 copies/ml, it is essential to step up adherence interventions, 
as discussed above. Once the viral load is confirmed on a second 
specimen to be >1 000 copies/ml despite adherence, the patient 
should be switched to a second-line regimen without undue delay. In 
summary, we advise a switch to a second-line regimen when 2 viral 
load measurements have been >1 000 copies/ml, preferably with 
the measurements taken 3 months apart with at least 4 weeks of an 
intensified adherence intervention in between. In patients with low 
CD4 counts (<100 cells/μl), this process should be expedited. 
Some patients have persistently detectable viral loads at low levels (200 
- 1 000 copies/ml). If patients have low level viraemia for a prolonged 
period (>1 year) or persistently low CD4 counts (<100 cells/μl) together 
with low-level viraemia despite adherence interventions, they should be 
switched to second-line ART.
10.1 Second-line ART
The following ritonavir-boosted PIs are recommended in conjunction 
with 2 NRTIs (Table 2):
•	 ATV/r
•	 LPV/r
•	 DRV/r (it is preferable to save this drug for third-line therapy, further 
discussed below).
Indinavir (IDV) is significantly more toxic than other PIs. SQV is less 
robust in terms of resistance than the 3 options listed. IDV and SQV 
confer no benefit over other options, and are therefore not recommended.
Boosting involves the addition of low-dose ritonavir, which inhibits PI 
metabolism, thereby boosting PI plasma concentration and prolonging 
its half-life. LPV is co-formulated with ritonavir in a heat-stable tablet 
(Aluvia) and is the best option in patients without a refrigerator (other 
PIs require ritonavir boosting with a separate ritonavir capsule that 
ideally requires refrigeration, although ritonavir capsules are stable 
at room temperature for 30 days). We recommend against the use of 
unboosted PIs.
If a patient was receiving a first-line combination of 2 NRTIs and a 
PI (boosted or unboosted), it is best to discuss the choice of second-line 
regimen with an experienced treater and consider a genotype resistance 
test. Second-line NNRTI plus NRTI regimens are often not effective in 
such patients because of NRTI mutations, while boosted PI regimens 
in second-line ART may remain effective. Decisions are therefore best 
guided by resistance testing.
10.2 Selecting second-line dual NRTIs
Because boosted PIs are robust drugs (i.e. resistance develops slowly) in PI-
naive patients, it is very likely that virological suppression will be achieved 
with good adherence, even if the 2 NRTIs used in second-line are partially 
compromised by NRTI resistance mutations (Tables 4 and 5).31
Certain NRTI combinations are contra-indicated for toxicity reasons 
(e.g. d4T plus ddI, or TDF plus ddI). TDF plus ABC is not recommended 
for second-line ART, as these agents share several resistance mutations. 
NRTI combinations advised for second-line regimens include either 
AZT plus 3TC, or TDF plus 3TC (FTC can be substituted in place of 
3TC), depending on the likely mutational profile selected during the 
patient’s first-line NRTI combination.
Even if 3TC (or FTC) is used in a failed first-line regimen and 
may, therefore, have selected for the M184V mutation which confers 
resistance to the agent, 3TC (or FTC) can be re-used in second-line 
therapy because of the capacity of the M184V mutation to partially 
restore susceptibility to AZT, d4T and TDF in the presence of thymidine 
analogue mutations (TAMs), and to partially restore susceptibility to 
TDF in the presence of the K65R mutation. The M184V mutation also 
reduces the replicative capacity of the virus.
Ideally, a resistance test should be performed at first-line failure to 
ensure that the patient does indeed have resistance (and the virus is not 
‘wild-type’) and to guide choices of second-line and future regimens. 
However, in many settings in the region, this is unaffordable and/or 
unavailable.
11.  Patients who return after 
defaulting therapy
We recommend restarting the same regimen if patients return to care 
after defaulting therapy and repeating HIV viral load measurements 
after 3 months; switching to a second-line regimen should be 
considered if the viral load is not suppressed at this point. If a patient is 
receiving first-line therapy, AZT could be substituted for D4T. However, 
we do not recommend substituting TDF, because, if the patient has 
pre-existing NNRTI and 3TC resistance, TDF resistance may rapidly 
result compromising its efficacy in second-line therapy. If a patient has 
multiple episodes of interruption, and, particularly, if they are beyond 
the first year of ART, then many clinicians would consider switching 
the patient to a second-line regimen, making the assumption that 
the multiple interruptions resulted in first-line resistance. Reasons 
for defaulting should be addressed and adherence support increased. 
Performing a resistance test after the patient has been off ART for 
longer than 4 weeks is of limited value as many resistance mutations are 
overtaken by wild-type when ART is stopped.
12. Drug interactions
There are many important drug interactions between ARV agents and 
other medications, as well as between certain ARV agents themselves. 
These interactions occur because of metabolism of ARV drugs by 
cytochrome P450 in the liver and intestine and induction or inhibition by 






ARVs of this and other enzyme systems and drug transporters. Certain 
of these drug interactions are discussed in these guidelines (e.g. the 
interaction between rifampicin and NNRTIs, PIs and RAL). The list of all 
potential drug interactions is, however, very long and therefore beyond 
the scope of this document. Knowledge of drug interactions is constantly 
evolving. Clinicians are advised to consult the package inserts of ARV 
agents and concomitant medication to assess for drug interactions and 
the following websites, which provide up-to-date information on drug 
interactions and the actions required to account for them:
•	 University of Liverpool Drug Interactions Charts: http://www.hiv-
druginteractions.org
•	 University of Cape Town Medicines Information Centre ARV 
interactions table: http://www.mic.uct.ac.za/?page_id=47
We advise that clinicians assess for potential drug interactions 
whenever patients start or switch to a new ARV drugs or regimens, and 
start new concomitant medications. In addition, herbal medications 
may also have interactions with ARVs.
13. ART in special populations 
13.1 TB
The ART regimen should be modified if necessary for compatibility with 
rifampicin – a critical component of the TB regimen that substantially 
reduces the risk of relapse after completing TB treatment. EFV is 
the preferred NNRTI for use with rifampicin. NVP is an alternative 
in patients with contra-indications for EFV (e.g. psychosis), but it 
carries a higher risk of hepatitis and virological failure when used with 
rifampicin.
The plasma concentrations of all boosted PIs are reduced to sub-
therapeutic ranges with rifampicin. Dose adjustment of some PIs can 
overcome this induction (Table 6), but there is a risk of hepatotoxicity. 
The patient will require counselling and ALT should be monitored 
frequently. An alternative approach is to replace rifampicin with 
rifabutin. However, rifabutin is expensive and not currently available 
at public sector TB clinics. Also, rifabutin is not co-formulated 
with other TB drugs such as rifampicin, and the evidence base for 
rifabutin in the treatment of TB is much less substantial than that for 
rifampicin.33 There is also uncertainty regarding the optimal dose of 
rifabutin with boosted PIs; current guidelines recommend 150 mg on 
alternate days. Rifabutin may be considered in patients not tolerating 
co-treatment with ART and rifampicin-based antitubercular therapy 
(e.g. patients unable to tolerate the increased LPV/r dose) or in ART-
experienced patients on an ART regimen that is not compatible with 
rifampicin (e.g. those on third-line ART with DRV/r). Rifabutin 
doses may require adjustment (Table 8). If rifabutin is unavailable and 
adjusted doses of PIs are poorly tolerated in patients on second-line 
ART, double-dose RAL (800 mg 12-hourly) may be substituted for the 
PI or triple NRTI therapy may be considered. Triple NRTI ART is, 
however, inferior to conventional ART and RAL is less robust than a 
PI in second-line therapy. Nevertheless, short-term use over 6 months 
is probably preferable to treating TB without rifampicin, which has a 
high risk of failure or relapse. ART and TB medication share many 
side-effects (Table 7).
Table 4. Mutations selected by first-line NRTI combinations*
First-line NRTIs NRTI mutations selected
3TC or FTC Select for M184V, which compromises both 3TC and FTC, and slightly impairs the 
activity of ABC and ddI, but increases susceptibility to AZT, D4T and TDF
AZT Selects for thymidine analogue mutations (TAMs) which may compromise all 
NRTIs†
D4T Selects for TAMs which may compromise all NRTIs
In a minority of patients, D4T may select for K65R which compromises TDF, ABC 
and ddI, but increases susceptibility to AZT 
TDF Selects for K65R which compromises TDF, ABC and ddI, but increases 
susceptibility to AZT
ABC Selects for L74V which compromises ABC and ddI
May also select for K65R which compromises TDF, ABC and ddI, but increases 
susceptibility to AZT
Selects for Y115F which decreases its susceptibility
*These mutations accumulate with time – the longer the patient has virological failure, the more of these mutations are likely to be selected.
†The presence of ≥3 TAMs, including M41L and L210W, confer intermediate- to high-level TDF resistance.
TAMs = thymidine analogue mutations; NRTI = nucleoside reverse transcriptase inhibitor; 3TC = lamivudine; FTC = emtricitabine; AZT = zidovudine; D4T = stavudine; TDF = tenofovir; 
ABC = abacavir.





AZT plus 3TC TDF plus 3TC*
D4T plus 3TC TDF plus 3TC* (preferably 
genotype first, given the 
increased risk of K65R on D4T 
in subtype C)32
TDF plus 3TC* AZT plus 3TC
ABC plus 3TC AZT plus 3TC
*3TC is interchangeable with FTC.
NRTI = nucleoside reverse transcriptase inhibitor; AZT = zidovudine; 3TC = lamivudine; D4T 
= stavudine; TDF = tenofovir; ABC = abacavir; FTC = emtricitabine. 








AIDS is the most frequent cause of death in pregnant women in many 
Southern African countries,34 and is a significant cause of morbidity 
and mortality in children born to HIV-infected women. Even where 
children are born HIV-negative, their mortality is significantly increased. 
Traditionally, the focus on HIV and pregnancy has centred on the 
transmission of HIV to children. This has lead to complex regimens to 
address concerns about efficacy and resistance. These guidelines attempt 
where possible to simplify this approach, to decrease transmission in both 
pregnant and breastfeeding mothers, and facilitate the continuum of care.
13.2.1 NNRTI and PI choice in pregnancy
•	 EFV has been shown to be teratogenic in primates, resulting in 
craniofacial abnormalities in exposed offspring. There have been 
Table 6. ART interactions with rifampicin and recommendations for co-administration
Class ARV agent Interaction Dose of ART drug with rifampicin
NRTIs All in class No significant pharmacokinetic interactions No dose adjustment required
NNRTIs EFV Mild reduction in EFV concentrations
In some patients, EFV concentrations may 
increase 
No dose adjustment required (600 mg nocte)
NVP Moderate reduction in NVP concentrations Use standard dosing, but omit the lead-in dose phase and 
start 200 mg NVP 12-hourly 
ETV Marked reduction in ETV concentrations Do not prescribe concomitantly
PIs LPV/r LPV plasma concentrations significantly 
decreased 
The preferable strategy is to double the dose of LPV/r to 
800/200 mg 12-hourly
Alternatively, add 300 mg ritonavir 12-hourly to standard 
dose of 2 tablets 12-hourly of LPV/r
There is an increased risk of hepatotoxicity with these 
strategies 
These dose adjustments can be made gradually over 1 - 2 
weeks*
SQV/ r SQV concentrations are significantly 
decreased
400 mg SQV plus 400 mg ritonavir 12-hourly
Increased risk of hepatotoxicity
All other PIs Marked reduction in PI concentrations Do not prescribe concomitantly
InSTI RAL Marked reduction in concentrations Double the dose of RAL to 800 mg 12-hourly
*The double dosing regimen is preferred as it is better tolerated. Dose adjustments should be continued for 2 weeks after rifampicin is stopped. 
ART = antiretroviral therapy; ARV = antiretroviral; NRTI = nucleoside reverse transcriptase inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; InSTI = Integrase 
inhibitor (integrase strand transfer inhibitor); EFV = efavirenz; NVP = nevirapine; LPV = lopinavir; LPV/r = lopinavir/ritonavir; SQV = saquinavir; SQV/r = saquinavir/ritonavir; RAL = raltegravir.
Table 7. Shared side-effects of TB treatment and ART 
Side-effects ART TB treatment 
Nausea AZT, ddI, PIs Pyrazinamide, ethionamide
Hepatitis NVP, EFV, PIs
(NRTIs can cause steatohepatitis)
Rifampicin, isoniazid, pyrazinamide and many second-line 
drugs including quinolones
Peripheral neuropathy D4T, ddI Isoniazid, ethionamide, terizidone/cycloserine
Renal impairment TDF Aminoglycosides
Rash NVP, EFV, RAL Rifampicin, isoniazid, pyrazinamide, ethambutol, streptomycin 
and many second-line drugs including quinolones
Neuropsychiatric EFV Terizidone/cycloserine, quinolones, isoniazid
AZT = zidovudine; ddI = didanosine; PIs = protease inhibitors; NVP = nevirapine; EFV = efavirenz; NRTIs = nucleoside reverse transcriptase inhibitors; D4T = stavudine; TDF = tenofovir.





EFV None Increase to 450 
mg/day




None Decrease to 150 mg 
every second day
ARV = antiretroviral; EFV = efavirenz; NVP = nevirapine; ATV = atazanavir; PIs = protease 
inhibitors.






isolated human case reports of myelomeningocele (neural tube 
defects) in infants following intra-uterine exposure to EFV. The drug 
is classified by the United States Food and Drug Administration 
(FDA) as a category D drug, meaning that ‘there is positive evidence 
of human fetal risk, but the benefits from use in pregnant women 
may be acceptable despite the risk (e.g. if the drug is needed in a life-
threatening situation or for a serious disease for which safer drugs 
cannot be used or are ineffective).’
•	 It should be noted, however, that data supporting this classification 
are not definitive. The incidence of neural tube defects and all 
congenital abnormalities among women exposed to EFV in the first 
trimester is similar to that of the general population, but insufficient 
numbers have been studied to state definitively that the drug is safe.35 
Most experts are willing to prescribe EFV for use in the second 
and third trimester, because the neural tube is formed in the first 4 
weeks of pregnancy. If a woman expresses the desire to fall pregnant, 
we suggest starting an alternative to EFV or switching from EFV 
to an alternative. However, if a woman falls pregnant on EFV we 
suggest continuing it (the neural tube forms in the first 4 weeks). In 
a pregnant woman not yet receiving ART, we suggest starting ART 
after the first trimester so that EFV can be used, unless the patient 
has advanced immunosuppression, in which case NVP can be started 
in the first trimester. Recent guidance from WHO is that EFV can 
be used throughout pregnancy; their review of current data on EFV 
safety and risk of teratogenicity was reassuring and, from a public 
health perspective, the need for simplicity and the toxicity associated 
with NVP were considered to outweigh concerns regarding unproven 
risks associated with EFV.36
•	 NVP-based ART is the preferred regimen for women in the first 
trimester of pregnancy. Initiating NVP at a CD4 count >250 cells/μl 
is associated with a much higher risk of rash-associated hepatitis. 
It should be noted that switching to NVP in women who plan to 
fall pregnant with CD4 counts that have increased to >250 cells/μl 
on ART is not associated with this increased risk. Nevertheless, a 
background risk of rash and hepatitis remains.
•	 In women who are wanting to fall pregnant if the CD4 count is >250 
cells/μl, or if there is intolerance to NVP, a boosted PI regimen can 
be used instead of NVP. Studies have shown that LPV concentrations 
are significantly reduced in pregnancy, but are adequate provided 
that LPV is the first PI that has been used. Once-daily dosing of 
LPV/r should not be used in pregnancy. Similarly, concentrations of 
boosted ATV are reduced in pregnancy, and the dose of ATV should 
be increased to 400 mg daily with 100 mg ritonavir daily. Unboosted 
ATV is not recommended in pregnancy.
13.2.2 General points
•	 Fertility choices in the context of HIV treatment are complex. 
Clinicians should check these choices at every patient visit to 
minimise risks. Adequate access to safe and effective contraception 
should be provided. For further guidance: 
Southern African HIV Clinicians Society. Guideline on safer conception in fertile 
HIV-infected individuals and couples. Southern African Journal of HIV Medicine 
2011;12:31-44.
•	 Clinicians should be aware that women may fall pregnant 
unintentionally, but that the response may still vary from welcoming 
the pregnancy to wanting a termination.
•	 In general, far too few women in the Southern African region receive 
prophylaxis for PMTCT. Every effort must be made to ensure rapid 
ascertainment of HIV status and access to appropriate PMTCT and 
ART.
•	 South African data suggest that most HIV transmissions to babies 
occur from HIV-positive mothers with CD4 counts <350 cells/μl. 
Rapid ART initiation for the mother at this level will have a large 
effect on both maternal and child health.
•	 All pregnant women of unknown HIV status or who were previously 
HIV-negative should be offered an HIV test, irrespective of previous 
sexual activity, marital status, social group or perceived HIV risk status. 
Ideally, testing should be repeated in the last trimester, as some studies 
have suggested a greater HIV acquisition risk during pregnancy.
•	 Mother-to-child transmission is a rapidly evolving field, and 
international guidelines should be monitored for major changes.
13.2.3 Recommendations
For women who are pregnant and not receiving ART, the following is 
recommended as best standard of care in situations where resources are 
available:
•	 All pregnant women should be initiated on triple-drug ART, if 
adequately prepared, irrespective of CD4 cell count and viral load. 
•	 HIV testing and staging must be done quickly and ART adherence 
counselling should be accelerated, with the aim to put women on 
treatment within 2 weeks of first visit (and more rapidly in the third 
trimester of pregnancy). Women who are being initiated onto ART 
for PMTCT should ideally be initiated after the first trimester, but 
women with a CD4 count <200 cells/μl or with severe HIV morbidity 
should be started in the first trimester.
•	 Women with baseline CD4 counts <350 cells/μl should have their 
ART continued indefinitely.
•	 Women who elect to breastfeed and have a baseline CD4 count >350 
cells/μl should continue ART until weaning has occurred.
•	 ART should be stopped after delivery in women with baseline CD4 
counts >350 cells/μl, provided that they are formula feeding. 
•	 If a woman presents during labour and is not receiving ART, single-
dose NVP should be given to mother and baby, with additional 
AZT and 3TC for 1 week or single-dose TDF/FTC to the mother 
to reduce the risk of NNRTI resistance developing (NVP has a very 
long half-life).
•	 Refer to PMTCT guidelines for recommended regimens for the baby.
13.3 ARV dosages in renal failure (Table 9)
Renal function is estimated either by the modified Cockgraft-Gault 
equation (see Table 9) or the modification of diet in renal disease 
(MDRD) method, which most laboratories report as ‘e-GFR’. The results 
of these formulae differ slightly, but either can be used for clinical 
management.
For peritoneal dialysis, the dose given with a creatinine clearance 
<10 should be given daily. For haemodialysis, the dose given with a 
creatinine clearance <10 should be given daily, but must be given after 
dialysis on dialysis days, to prevent the drug from be dialysed out.
13.4 ARV dosages in liver impairment
Unlike in renal impairment, there is no blood test that can accurately 
quantify liver impairment. Child-Pugh class C may require dose 







adjustment for the relevant ARVs listed in Table 10. In general, 
the combination of TDF with 3TC (or FTC) and EFV (or RAL) is 
regarded as the least hepatotoxic. If the patient has active hepatitis B, 
discontinuation of ARVs that have activity against hepatitis B (TDF, 
3TC and FTC) can cause severe flares of hepatitis (see section 13.5).  
13.5 Hepatitis B co-infection
Hepatitis B is a common co-infection in Southern Africa with HIV, 
with significant implications for progression to cirrhosis, as well as for 
treatment options. Clinicians are encouraged to support current efforts 
in the region to vaccinate all children for hepatitis B, and to extend 
coverage to eligible adults. Access to vaccination, laboratory resources 
and treatment options are all limited to some extent in Southern African 
countries, and the recommendations below should each be considered 
in the light of the local context.
All HIV-infected patients should be screened for active hepatitis B 
(limiting screening to those with liver function abnormalities will miss 
many cases as liver enzymes are often normal in hepatitis B infection). 
Hepatitis B surface antigen is an appropriate screening test. Hepatitis 
B DNA viral load correlates with disease progression and may be used 
to monitor anti-hepatitis B therapy, but it is expensive and availability 
is limited. 
Hepatitis B/HIV co-infection is associated with:
•	 an increased risk of chronic liver disease
•	 a higher hepatitis B viral load
•	 diminished responses to hepatitis B vaccine 
•	 poorer responses to interferon-alpha treatment
•	 an increased incidence of drug-induced hepatotoxicity (particularly 
with NVP)
•	 a flare of hepatitis within 3 months of commencing ART (due 
to hepatitis B-IRIS, which is difficult to differentiate from drug 
hepatotoxicity).
Drugs directed against hepatitis B that have no or minimal anti-
HIV activity (e.g. entecavir and telbivudine) are largely unavailable 
or extremely expensive in our region. For practical purposes, the only 
available therapy is to use ARVs that also have anti-hepatitis B activity 
(TDF, 3TC and FTC). As with HIV, these drugs suppress hepatitis B, but 
do not eradicate it. Effective treatment prevents or slows progression 
to cirrhosis. 
Indications for specific hepatitis B treatments37 include any one of 
the following:
•	 a positive test for hepatitis B e antigen
•	 raised ALT (>2x the upper limit of normal (ULN)) 
•	 evidence of fibrosis on biopsy or on appropriate imaging
•	 a hepatitis B viral load >10 000 copies/ml (or 2 000 IU/ml).
If any of the above criteria are met, then ART should be commenced 
irrespective of the CD4 count. The ART regimen should include TDF 
and 3TC (or FTC). Using 3TC without including TDF leads to hepatitis 
B resistance in 80 - 90% of patients after 5 years of treatment. If patients 
meet criteria for switching to a second-line ART regimen (to treat their 
HIV), this combination (TDF and 3TC/FTC) should be continued to 
suppress HBV infection, as interruption of TDF and/or FTC/3TC has 
been associated with life-threatening hepatitis flares. The second-line 
ART regimen should be shaped around these 2 drugs in discussion 
with an experienced treater. NVP should be avoided in patients with 
hepatitis B co-infection.
In patients with hepatitis B and renal dysfunction, the use of 
TDF may be considered with dosing frequency adjustment based 
on creatinine clearance (see package insert) and more frequent 
creatinine monitoring. If renal dysfunction is severe or renal function 
deteriorates with TDF, 3TC monotherapy (with or without pegylated 
interferon-alpha) should be considered. Pegylated interferon-alpha is 
very costly. For further guidance: 
Southern African HIV Clinicians Society. Management of HIV-hepatitis B co-infection. 
Southern African Journal of HIV Medicine 2011;12:27-33.
13.6 Malaria
There are several drug interactions between antimalarials and ARVs:
•	 Artemether-lumefantrine (Coartem) can be safely administered 
with NVP. There are no data yet on interactions with EFV, but the 
combination is likely to be safe. Boosted PIs dramatically increase 
the plasma concentrations of lumefantrine, but a dose reduction is 
not recommended, as the toxicity threshold of lumefantrine seems 
to be high. Close monitoring for toxicity is recommended when 
co-administering artemether-lumefantrine with ART.
•	 Quinine concentrations are significantly decreased by LPV/r, 
probably due to induction of metabolism by ritonavir. It is likely 
that quinine concentrations will also be reduced by EFV and NVP; 
therefore, quinine should be avoided in patients receiving PIs or 
NNRTIs. Patients with severe malaria should receive artesunate 
and those with milder malaria should be treated with artemether-
lumefantrine.
•	 Among drugs used for chemoprophylaxis, there are no clinically 
significant pharmacokinetic interactions between ARVs and 
mefloquine or doxycycline. However, mefloquine and EFV both 
Table 9. ARV dosage adjustments in renal failure
Creatinine clearance 
Drug 10 – 50 <10
AZT Unchanged 300 mg daily
ddI >60 kg body weight: 
200 mg daily
<60 kg body weight: 
150 mg daily
>60 kg body weight: 
100 mg daily
<60 kg body weight: 
75 mg daily
3TC 150 mg daily 50 mg daily





*Source: Bartlett JG. Medical care of patients with HIV Infection 2010, and The Sanford guide to 
Antimicrobial Therapy 2010.
AZT = zidovudine; ddI = didanosine; 3TC = lamivudine; D4T = stavudine; ABC = abacavir; 
TDF = tenofovir; PI = protease inhibitor; NNRTI = non-nucleoside reverse transcriptase 
inhibitor.
The modified Cockgraft-Gault equation:
 (140 - age) x ideal weightcreatine clearance* =   serum creatinine
*For women, multiply the total by 0.85.






cause frequent neuropsychiatric side-effects; therefore, doxycycline 
is the preferred chemoprophylactic agent for patients receiving EFV.
•	 There are several interactions with atovaquone-proguanil (Malanil). 
Atovaquone concentrations are reduced by PIs and EFV. It is also 
likely that NVP decreases atovaquone concentrations. Proguanil 
concentrations are also reduced by PIs and EFV. Use of atovaquone-
proguanil is therefore best avoided in patients receiving PIs or NNRTIs.
14.  ARV toxicity monitoring and 
management
Currently used ART is generally well tolerated. Many adverse drug 
reactions are mild and occur only in the first few weeks of therapy. If 
toxicity does not resolve or is severe, then the offending drug should be 
substituted as indicated below. It is important to ensure that the viral 
load is suppressed before substituting a single drug, otherwise resistance 
may develop to the new drug, consequently compromising future 
regimens. Single drug substitutions can be performed safely in the first 
6 months of ART without measuring the viral load.
It is rarely necessary to stop the entire ART regimen due to toxicity. 
It is advised to switch only the culprit drug and continue the rest of 
the ART regimen. In certain life-threatening situations (e.g. hepatitis 
with liver failure, lactic acidosis), it may be necessary to cease use of all 
ARVs. In patients with severe NNRTI-related toxicity, a PI should be 
substituted. If this is undesirable (e.g. in a patient receiving TB therapy), 
use of the NNRTI should be stopped and 2 NRTIs should be continued 
for 1 week to reduce the risk of resistance developing to NNRTIs, which 
have a long half-life.
14.1 Haematological toxicity 
Cytopaenias occur commonly in HIV infection without exposure to 
ART. Patients receiving AZT, D4T or cotrimoxazole may experience 
abnormalities in their FBCs. Significant bone marrow toxicity from 
cotrimoxazole generally only occurs with high doses used for treating 
opportunistic infections. Patients receiving prophylactic cotrimoxazole 
uncommonly develop isolated neutropaenia. FBC monitoring is 
necessary with AZT; this should be performed monthly for 3 months, 
then after 6 months of therapy and thereafter if clinically indicated (it 
is unusual to see haematological toxicity occurring after 6 months). 
The main problem arising from AZT use is anaemia and neutropaenia; 
platelet counts generally rise with use of the drug. Management 
guidelines are provided in Table 11. Macrocytosis is usual with D4T 
and AZT therapy; there is no need to measure vitamin B12 and folate 
concentrations, unless there are other indications that these may be 
deficient. 
Pure red cell aplasia, which presents with severe anaemia and low 
reticulocyte index, has rarely been associated with 3TC. A bone marrow 
examination should be performed to confirm the condition. Parvovirus 
B19 infection should be excluded (a polymerase chain reaction (PCR) 
test should be requested on blood sent in an ethylenediaminetetra-
acetic acid (EDTA) tube). 
14.2 Hepatotoxicity
•	 Liver function tests (LFTs) should be performed at ART initiation 
and measurement interval should be tailored thereafter to individual 
drug regimens. The full panel of LFTs is expensive; therefore, it 
Table 10. Prescribing ARVs in liver impairment
Class Drug Prescribing notes
NRTIs ABC Reduce adult dose to 200 mg bd for significant liver impairment
Contra-indicated in severe hepatic impairment
ddI Use with caution: recent reports implicate use as a risk factor for the development of hepatic 
decompensation in patients being treated for cirrhosis due to hepatitis C
FTC In patients with chronic hepatitis B, there is a risk of rebound hepatitis when FTC is discontinued or if 
hepatitis B resistance to FTC develops
3TC In patients with chronic hepatitis B, there is a risk of rebound hepatitis when 3TC is discontinued or if 
hepatitis B resistance to 3TC develops
D4T Use with caution and never combine D4T and ddI in patients with liver disease
TDF In patients with chronic hepatitis B, there is a risk of rebound hepatitis when TDF is discontinued 
AZT Decrease dose by 50% or double dosage interval if significant liver disease
NNRTIs EFV Caution should be exercised in administering EFV to patients with liver disease
Therapeutic drug monitoring should be done if available
NVP Avoid if significant hepatic impairment or active hepatitis B or C
PIs ATV Avoid in severe hepatic impairment
IDV Reduce unboosted adult dose to 600 mg 8-hourly if significant hepatic impairment
LPV/r LPV is highly metabolised in the liver and concentrations may be increased in patients with hepatic 
impairment
Therapeutic drug monitoring should be done if available
DRV Use with caution or avoid if significant liver disease
SQV Avoid: there have been reports of worsening liver disease and development of portal hypertension after 
starting SQV in patients with severe liver disease
NRTIs = nucleoside reverse transcriptase inhibitors; ABC = abacavir; ddI = didanosine; FTC = emtricitabine; 3TC = lamivudine; D4T = stavudine; TDF = tenofovir; AZT = zidovudine; 
NNRTIs = non-nucleoside reverse transcriptase inhibitors; EFV = efavirenz; NVP = nevirapine; PIs = protease inhibitors; ATV = atazanavir; IDV = indinavir; LPV/r = lopinavir/ritonavir; 
DRV = darunavir; SQV = saquinavir.







is recommended that only ALT is monitored, as this is the most 
sensitive indicator of drug-induced liver injury. The full LFT 
profile should be requested in patients with symptoms suggestive of 
hepatitis. All ARV classes have been associated with hepatotoxicity – 
most commonly NNRTIs. The NRTIs very rarely present with acute 
hepatitis. Mild ALT elevations occur very commonly and usually 
transiently with many drugs in general. ALT elevations >5xULN are 
significant.
•	 Ideally, in patients starting NVP, ALT should be monitored at 2, 4, 8 
and 12 weeks after initiation. If monitoring is performed, a system 
should be in place to obtain the result and contact the patient; routine 
ALT monitoring makes little sense in settings where the result will only 
be available when the patient is seen in 2 - 4 weeks, or where the patient 
cannot be contacted. It is essential to educate all patients starting NVP 
about the symptoms of hepatitis (nausea, vomiting, anorexia, malaise, 
jaundice and right upper quadrant pain) and drug rash, which is 
frequently associated with hepatitis. If such symptoms develop, ALT 
should be determined urgently.
•	 Hepatotoxic drugs should be discontinued at high levels of LFT 
abnormality (Table 12) or at lower levels if any symptoms of hepatitis 
appear. Rechallenge may be considered in selected cases; a specialist 
should be consulted. If hepatitis occurs together with a rash or fever, or 
with other systemic involvement, then rechallenge with NNRTIs, ABC 
or cotrimoxazole should not be attempted. 
•	 Prolonged use of NRTIs, especially D4T and ddI, may cause fatty 
liver. Typically, ALT concentration is more signficantly elevated 
than AST, and the concentration of cannalicular enzymes (GGT 
and alkaline phosphatase (ALP)) is more significantly elevated 
than the transaminases. Non-tender hepatomegaly may be present. 
Ultrasound or computed tomography (CT) imaging may show 
decreased hepatic density. The condition is not benign and fibrosis 
has been reported with long-term ddI use. Patients should be 
advised to avoid alcohol. Patients receiving d4T or ddI should be 
switched to safer NRTIs.
•	 In patients with severe hepatitis or jaundice, the international 
normalised ratio (INR) should be assessed, as well as features of 
hepatic encephalopathy (i.e. features of hepatic failure).
•	 If the concentration of cannalicular enzymes is more significantly 
elevated than ALT, or if conjugated bilirubin is elevated, an ultrasound 
of the liver should be conducted to exclude biliary obstruction. 
•	 Isolated unconjugated hyperbilirubinaemia (drug-induced Gilbert’s 
syndrome) is associated with certain PIs (IDV and especially 
ATV). Although this is a benign condition, it is often cosmetically 
unacceptable to patients.
•	 Patients with underlying hepatitis B or C infection frequently 
experience a ‘flare’ of hepatitis when ART is commenced, as a 
consequence of IRIS. Hepatitis B can also flare when ARVs that have 
activity against hepatitis B (TDF, 3TC and FTC) are discontinued or 
when hepatitis B resistance develops.
•	 Many other drugs can cause hepatotoxicity, notably anti-TB agents 
(including prophylactic isoniazid) and azoles. Cotrimoxazole is a 
rare cause of hepatitis, usually with a cholestatic picture.
14.3 Hyperlactataemia
•	 This side-effect has become less common with fewer patients 
starting ART with D4T and with the use of lower doses. However, 
clinicians should remain vigilant in patients receiving D4T and be 
aware that this side-effect can occur with all other NRTIs, although 
very rare with ABC, TDF, 3TC and FTC. Mildly elevated lactate 
is not uncommon in patients treated with NRTIs, but is generally 
asymptomatic. Asymptomatic elevated lactate does not predict the 






















Hb = haemoglobin; AZT = zidovudine. 
Table 12. Guidelines for managing hepatotoxicity
ULN* <2.5 x ULN 2.5 - 5 x ULN >5 x ULN
ALT Monitor Repeat at 1 week Discontinue relevant drug(s)
ALP Monitor Repeat at 2 weeks Ultrasound 
Consider biopsy
Bilirubin Repeat at 1 week Discontinue relevant drug(s) Discontinue relevant drug(s)
*Any elevations with symptoms of hepatitis (nausea, vomiting, right upper quadrant pain) should be regarded as an indication to stop relevant drugs.
ULN = upper limit of normal; ALT = alanine transaminase; ALP = alkaline phosphatase.
The potential of NRTIs to cause elevated lactate varies (from 
most likely to least likely): 
stavudine/didanosine > zidovudine > tenofovir/emtricitabine/
lamivudine/abacavir






development of lactic acidosis; it is therefore unnecessary to monitor 
levels in asymptomatic patients.
•	 Lactic acidosis is a serious, rare, potentially fatal side-effect 
of NRTIs, most commonly associated with D4T, particularly 
when combined with ddI. Symptomatic hyperlactataemia without 
acidosis is more common, but seldom seen with the safer NRTIs 
recommended.
•	 The combination of D4T and ddI is associated with a high risk of 
symptomatic hyperlactactaemia or lactic acidosis (particularly in 
pregnancy). This combination should therefore be avoided. 
•	 Symptoms are non-specific and include nausea and vomiting, 
abdominal pain, dyspnoea, fatigue and weight loss. 
•	 Risk factors for hyperlactataemia include:
•	 female gender
•	 obesity
•	 the use of NRTIs for >6 months
•	 the development of NRTI-induced peripheral neuropathy or fatty 
liver.
•	 A raised lactate of >5 mmol/l together with metabolic acidosis 
confirms the diagnosis of lactic acidosis. Low serum bicarbonate 
(<20 mmol/l) is the most sensitive marker of acidosis. Associated 
abnormalities include elevated AST and ALT, lactate dehydrogenase 
and creatinine kinase. Treatment is supportive. High-dose riboflavin 
(50 mg) and L-carnitine may be used (no evidence for either 
intervention). Management depends on the lactate and bicarbonate 
concentrations:
•	 Lactate <5 mmol/l and bicarbonate >20 mmol/l and minor 
symptoms. NRTIs should be switched to agents less associated 
with hyperlactataemia: TDF or ABC (if these are unavailable, then 
AZT could be used) plus FTC or 3TC. Symptoms and serial lactate 
should be monitored for several months (lactate levels decrease 
slowly over weeks). 
•	 Lactate >5 mmol/l and bicarbonate >15 mmol/l. NRTIs should 
be discontinued and the patient should be admitted. If the patient 
is on an NNRTI regimen, a boosted PI should be added. If the 
patient has already failed an NNRTI and is on a boosted PI, RAL 
and/or etravirine (ETV) should be added, if available, or the 
patient should be continued on the boosted PI only. When lactate 
has normalised, the patient should be switched to TDF or ABC 
with 3TC or FTC, as above. 
•	 Lactate >5mmol/l and bicarbonate <15 mmol/l. NRTIs should 
be discontinued and the patient should be admitted, preferably 
to an intensive care unit. If the patient is on an NNRTI regimen, 
a boosted PI should be added. If the patient has already failed an 
NNRTI regimen and is receiving a boosted PI, RAL and/or ETV 
should be added, if available, or the patient should be continued 
on a boosted PI only. Bicarbonate replacement is controversial, 
but most experts would use this strategy to partially correct severe 
acidosis. Broad-spectrum antibiotics are recommended as sepsis 
can mimic NRTI-induced lactic acidosis (this can be discontinued 
if procalcitonin is normal). On recovery, all NRTIs should be 
avoided in future regimens (some experts would be prepared to 
use safer NRTIs, as above).
For further guidance:
Southern African HIV Clinicians Society. Guidelines for the prevention, diagnosis 
and management of NRTI-associated symptomatic hyperlactataemia and lactic 
acidosis. Southern African Journal of HIV Medicine 2006;7:8-15.
14.4 Dyslipidaemia
•	 PIs, with the exception of unboosted ATV, can cause fasting 
hypertriglyceridaemia and elevated LDL-cholesterol. Boosted ATV 
is associated with less severe dyslipidaemia. D4T can cause mild 
hypertriglyceridaemia. PIs are associated with the most marked 
elevation of triglycerides. EFV can cause elevated total cholesterol and 
mild hypertriglyceridaemia.
•	 Diet and lifestyle modification should always be advised. Diet is 
more effective for controlling hypertriglyceridaemia than 
hypercholesterolaemia. Other cardiovascular risk factors should be 
addressed.
•	 If patients receiving PIs develop dyslipidaemia that warrants lipid-
lowering therapy, they should be switched to boosted ATV, if 
possible, rather than adding therapy for the dyslipidaemia. Switching 
the PI to RAL is another option, because RAL has a favourable lipid 
profile. However, RAL should only be used in a regimen with 2 other 
fully active drugs. 
•	 Marked hypertriglyceridaemia (>10 mmol/l) can cause pancreatitis 
and requires urgent treatment with diet, fibrates and switching to 
boosted ATV (fibrates can be stopped after 1 month followed by 
reassessment). Indications for statin therapy in HIV-infected patients 
should be the same as in uninfected patients, according to the 
Framingham heart disease risk score. Many statins have interactions 
with PIs that can lead to potentially toxic statin concentrations, 
with the exception of pravastatin and fluvastatin, which can be 
used without dose adjustment. Atorvastatin concentrations are 
significantly raised by PIs, but lower doses (e.g. 10 mg daily) can be 
used. Lovastatin and simvastatin should not be co-administered with 
PIs, as their concentrations are dramatically increased and severe 
rhabdomyolysis has been reported.
•	 We suggest assessing lipids after 3 months on a PI regimen. If normal 
at this stage, the assessment should be performed annually only in 
those with other cardiovascular risk factors.
14.5 Lipodystrophy
•	 Long-term ART use may cause chronic lipodystrophic changes, 
with a change in body fat distribution. This can present with fat 
accumulation (visceral obesity, breast enlargement, ‘buffalo hump’ 
or lipomata) or fat loss (lipo-atrophy, presenting as facial, limb and 
buttock wasting) or with both. 
•	 The thymidine analogue NRTIs (AZT and especially D4T) are 
associated with fat loss. 
•	 Previously, PIs were thought to be the cause of lipohypertrophy. 
However, more recent studies have shown that all classes of ARVs 
are associated with fat gain to the same extent. Furthermore, 
longitudinal studies comparing HIV-uninfected people with HIV-
infected people on long-term ART have demonstrated that the 
extent and distribution of fat gain are similar. These data suggest 
that fat gain is a consequence of treating HIV. The appearance 
of the fat gain is particularly unsightly when accompanied by 
subcutaneous fat loss.
•	 The re-distribution of body fat may be cosmetically unacceptable to 
the patient, resulting in discontinuation of ART. 
•	 Lipo-atrophy improves when D4T/AZT is substituted with TDF or 
ABC, but resolution is very slow and usually incomplete; therefore, 
it is important to recognise lipo-atrophy early or, better still, to use 
NRTIs that are not associated with the condition. 







•	 There is no good evidence to support the switching of ARVs in 
patients with fat accumulation. Exercise is of some assistance in 
reducing abdominal fat. Surgery should be considered in selected 
cases with focal fat gain (e.g. those with prominent ‘buffalo humps’). 
Metformin modestly reduces weight and improves insulin resistance 
in patients with the metabolic syndrome or isolated dysglycaemia.
•	 Visceral fat accumulation is associated with insulin resistance and 
dyslipidaemia. Other cardiovascular risk factors should be addressed 
in all patients.
14.6 Hypersensitivity
•	 Rash with NNRTIs is common (more severe and frequent with NVP) 
in the first 6 weeks of therapy. If the rash is accompanied by systemic 
features (e.g. fever, elevated ALT or hepatitis), mucosal involvement 
or blistering, the NNRTI should be discontinued immediately and 
rechallenge must not be performed. If the rash is mild and occurs 
without these features, the NNRTI can be continued and the rash can 
be treated symptomatically with antihistamines and, possibly, topical 
steroids. Systemic steroids should not be used.
•	 In patients who develop rashes during the low-dose NVP ‘lead in’ 
phase (200 mg daily), the dosage must not be increased to 200 mg 
12-hourly until the reaction has completely resolved. This ‘treat-
through’ approach is only acceptable if the patient can carefully be 
observed, otherwise NVP should be substituted.  
•	 There is a possible cross-reaction between NVP and EFV, although 
most studies report no evidence of this. It is acceptable to substitute 
EFV for NVP in the event of hypersensitivity, unless the reaction 
was severe. There are hardly any data on substituting NVP for EFV 
in the event of hypersensitivity; therefore, this substitution is not 
recommended.38
•	 ABC hypersensitivity is primarily a systemic reaction occurring 
within the first 8 weeks of therapy in approximately 3% of cases. 
Fatalities may occur on rechallenge. Therapy must be discontinued 
and never re-introduced. The manifestations of hypersensitivity 
include fever, rash, fatigue and abdominal or respiratory symptoms. 
If there is any doubt concerning the diagnosis (e.g. if the patient 
has a cough with fever), then the patient should be admitted for 
observation. Symptoms progress if hypersensitivity is present. The 
hypersensitivity reaction has been shown to occur on a genetic 
basis, being virtually confined to the HLA-B*5701 allele, which is 
very uncommon in Africans. If affordable and available, this allele 
should be excluded prior to using ABC in populations where the 
allele occurs.
14.7 Nephrotoxicity
Analysis for serum creatinine and urine proteinuria must be performed 
at baseline in all patients to detect sub-clinical renal disease, as there 
is an increased risk of renal failure in HIV infection due to a variety of 
causes. The dose of NRTIs needs to be adjusted in renal failure (Table 9). 
In a minority of patients, TDF may cause a tubular wasting syndrome 
(including wasting of phosphate and potassium). If patients receiving 
TDF develop muscle weakness or other muscle symptoms, then 
potassium and phosphate levels must be assessed. TDF can also cause 
acute renal failure, but this is uncommon. TDF should be discontinued 
immediately in patients with acute renal failure; it can be recommenced 
when the renal failure has resolved only if an alternative cause of renal 
failure is established.
It is essential to estimate the creatinine clearance before commencing 
TDF, which should not be used if the clearance is <50 ml/min. For 
patients receiving TDF, creatinine should be monitored at 3 months, 
6 months and then 6-monthly. In high-risk patients (particularly 
those with co-existent hypertension or diabetes), creatinine should 
also be checked at 1 and 2 months. Long-term use of TDF with 
other nephrotoxic agents (e.g. aminoglycosides or NSAIDs) should 
be avoided. In patients in whom TDF is avoided because creatinine 
clearance is <50 ml/min at baseline, it may be possible to switch to 
TDF at a later point if renal function improves. This is often the case if 
patients had chronic diarrhoea or other opportunistic infections at the 
time of ART initiation.
14.8 Neuropsychiatric toxicity
AZT and RAL frequently cause headaches when started, but this usually 
resolves. EFV frequently causes neuropsychiatric effects in the first few 
weeks of therapy, typically presenting with insomnia, vivid dreams and 
dizziness. Both dysphoria and euphoria may occur. Fortunately, these 
features subside in the majority of patients within the first 4 - 6 weeks. 
Psychosis may occasionally occur. If the neuropsychiatric effects of EFV 
are not tolerated, then the patient should be switched to NVP or another 
alternative.
14.9 Dysglycaemia
The older PIs, notably IDV, may cause diabetes. However, the newer 
PIs (ATV, DRV and LPV) do not. Visceral fat gain, which occurs to a 
similar extent with all ARV classes, is associated with insulin resistance. 
Blood glucose should be assessed serially in these patients as part of a 
cardiovascular risk assessment.
14.10 Gynaecomastia
Gynaecomastia involves the development of breast tissue in men. This 
is not related to lipodystrophy. It may be bilateral or unilateral. Serum 
testosterone should be measured and replacement therapy given if this 
is low. Gynaecomastia is most consistently associated with EFV, so 
patients should be switched to NVP or another alternative.
15.  Immune reconstitution 
inflammatory syndrome (IRIS)
Approximately 10 - 20% of patients who start ART with advanced 
immunosuppression experience clinical deterioration during the first 
months due to IRIS. Two forms are recognised: unmasking IRIS occurs in 
patients who have an unrecognised opportunistic infection when ART is 
started and who then present with an exaggerated inflammatory features 
of that infection during early ART due to it being ‘unmasked’ by recovering 
immunity; paradoxical IRIS occurs in patients who are being treated for 
an opportunistic infection when they start ART, but who develop an 
immune-mediated worsening or recurrence of features of that infection 
after starting ART. IRIS is most frequently described in association 
with TB and CM. Skin conditions such as molluscum contagiosum and 
Kaposi’s sarcoma may also worsen due to IRIS. The diagnosis of IRIS 
can be difficult, mainly because there is no confirmatory diagnostic test. 
Diagnosis relies on recognition of the characteristic clinical presentation, 
ensuring that opportunistic infection(s) are correctly diagnosed, and 
excluding alternative causes for deterioration such as drug resistance 
(e.g. MDR-TB). Case definitions for TB and cryptococcal IRIS have been 
published.39,40 It is important to ensure that the underlying opportunistic 






infection is treated appropriately. ART should be continued, unless 
IRIS is life-threatening (e.g. neurological involvement in TB-IRIS with 
depressed level of consciousness). Corticosteroids have been shown 
to reduce morbidity and improve symptoms in paradoxical TB-IRIS,41 
and can be used in mycobacterial and fungal forms of IRIS when other 
causes for deterioration have been excluded, and particularly when IRIS 
features are severe.42 Practical guidelines for TB-IRIS management have 
recently been published.43
16. Third-line ART
Third-line ART (also referred to as ‘salvage’ therapy) is used when a 
patient has experienced virological failure on drugs from the NRTI, 
NNRTI and PI classes (with documented PI resistance). Before 
considering third-line therapy, adherence interventions should be 
intensified and, if there is still no viral suppression, a resistance test must 
be performed to confirm the presence of resistance to the PI being used 
in second-line therapy. This test is very expensive and the patient must 
be on the failing ART at the time, as ‘wild-type’ HIV is more fit and 
outgrows the resistant mutant population which therefore cannot be 
detected within some weeks/months after cessation of ART. However, 
third-line regimens are also extremely expensive and are not justified 
if the patient does not have resistance necessitating such a switch. Data 
show that currently most patients failing second-line regimens in SA 
are infected with an HIV virus without PI mutations. In these patients, 
improved adherence is required rather than third-line regimens. The 
decisions regarding treatment choices in third-line therapy are complex 
and need to be guided by resistance patterns found on resistance testing. 
It is essential that resistance tests are interpreted in conjunction with a 
full ART history by an expert. 
Current international guidelines promote the idea that virological 
suppression is a realistic goal for third-line therapy. This is certainly true 
with the availability of several new classes of ARV agents (entry inhibitors 
and InSTIs) together with newer PIs (DRV and tipranavir) and NNRTIs 
(ETV).44 As these drugs become available in the region for patients who 
require them, they provide the possibility of effective suppression with 
third-line therapy. DRV, ETV and the InSTI RAL are now registered in 
South Africa. No firm recommendations for a generic third-line regimen 
can be made and regimen choice should be individualised. An expert 
treater should always be consulted. A few guidelines regarding third-line 
ART regimens are further discussed:
•	 There is a need for specific adherence counselling in patients 
preparing to start third-line ART, with a frank discussion that this 
regimen is likely to be their last option for the foreseeable future.
•	 First-generation NNRTIs (NVP and EFV) have no place in third-line 
therapy as they do not impair viral fitness.
•	 A boosted PI with the broadest resistance profile should be selected 
(this is currently DRV).45 DRV must be used twice daily in this 
context (600 mg 12-hourly with 100 mg ritonavir 12-hourly). LPV 
may be used if the drug is still active based on a resistance test (e.g. if 
the patient failed second-line ATV therapy).
•	 The addition of 3TC (or FTC) is recommended as the M184V 
mutation that it selects for impairs viral replication. Other NRTIs 
(the most active based on resistance testing) should also be added.
•	 Consideration of the addition of other salvage drugs (e.g. RAL46 and/or 
ETV47,48) will depend on genotype resistance test result and cost issues. 
RAL is preferred because it belongs to an entirely new class with no 
risk of cross-resistance from prior ART exposure in first- and second-
line therapy. Because most patients are not receiving an NNRTI at the 
time of failing second-line therapy when a genotype resistance test 
is typically performed, prior NNRTI mutations related to first-line 
NNRTI failure may be archived at this time. Therefore, it is difficult 
to be certain from this genotype as to whether ETV is compromised; 
however, data from South Africa suggest that the majority of patients 
who have failed NVP or EFV are still susceptible to ETV.49
•	 We advise against double ritonavir-boosted PIs.1
•	 If viral suppression is not achieved on salvage therapy, there is still 
benefit in continuing failing ART because of the residual partial 
activity and ‘crippling’ effect of such ART. ‘Crippling’ describes the 
fact that mutant viruses often have less replicative capacity. Provided 
that the viral load can be maintained below 10 000 copies/ml, the 
CD4 count will usually be maintained or even increase.30
For further guidance, the Southern African HIV Clinicians Society will 
be publishing ART resistance guidelines in late 2012.
17. Support and counselling
17.1 ART-related counselling
Many patients are afraid of starting ART. The patient should be 
reassured that the drugs work and that side-effects are usually minor 
and transient, or manageable. The patient should be given a treatment 
plan, specifying the reasons for commencing therapy and the drugs to 
be used (with names and details including the appearance of each drug, 
when and how they are to be taken, and a brief indication of anticipated 
side-effects and toxicity). 
Adherence in the order of 95 - 100% is required for virological 
suppression. Poor adherence results in the development of drug 
resistance. The desire to stop therapy or alter the number or timing 
of the drugs must be avoided. The patient must be encouraged to 
discuss drug-related issues with his/her clinician before any changes 
are made.
17.2 Lifestyle, nutrition, traditional 
medication and supplements
A healthy lifestyle is recommended, including a balanced diet, plenty of 
exercise, giving up smoking, moderating alcohol and having a positive 
outlook on the future. Various adjuncts to therapy are widely used in the 
community. These include specific diets, food/nutritional supplements, 
vitamins and so-called immune ‘boosters’. Scientific evidence to support 
the use of these is largely absent. Some herbs and high doses of trace 
elements and fat-soluble vitamins may cause harm and ought to be 
discouraged. There are also potentially important drug interactions 
between some herbal remedies and ARVs. For further guidance: 
Southern African HIV Clinicians Society. Nutrition and HIV/AIDS: Nutritional 
guidelines for HIV-infected adults and children in Southern Africa: Meeting the needs. 
Southern African Journal of HIV Medicine 2007;8:22-32. 
Southern African HIV Clinicians Society. Nutrition and HIV/AIDS: Nutritional 
guidelines for HIV-infected adults and children in Southern Africa: Meeting the needs. 
Southern African Journal of HIV Medicine 2008;9:34-59.
17.3 Immunisations
HIV infection is associated with a suppression of both humoral and 
cell-mediated immune response, which may impair the response to 
vaccinations reducing their efficacy, especially if the CD4 count is <200 
cells/μl. The safety of live attenuated vaccination is also modified by 
HIV-infection and live vaccines are contra-indicated in symptomatic 
HIV disease or if the CD4 count is <200 cells/μl. The decision to use a 
vaccine must be based on best assessment of risks and benefits. 







Travellers to areas endemic for malaria and yellow fever need to be 
cautioned. The forested regions where contact with the mosquito vector 
and the virus is possible must be avoided. Yellow fever vaccination 
poses a risk to HIV-positive travellers whose CD4 count is <200 cells/μl. 
Such persons should be encouraged to make alternative arrangements 
or to travel with documentation that permits travel without prior 
vaccination. 
17.4 Opportunistic infections 
The use of appropriate prophylaxis (primary or secondary) is essential 
in patients initiating ART. In general, prophylaxis can be discontinued 
once the CD4 count has increased to 200 cells/μl (but certain minimal 
durations of prophylaxis apply for secondary prophylaxis – local and 
international guidelines should be consulted). 
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Appendix: WHO stage 3 and 4 
conditions (2006 revision)
WHO stage 3 conditions
•	 unexplained severe weight loss (over 10% of presumed or measured 
body weight)
•	 unexplained chronic diarrhoea persisting for longer than 1 month
•	 unexplained persistent fever (intermittent or constant for longer than 
1 month)
•	 persistent oral candidiasis
•	 oral hairy leukoplakia
•	 pulmonary TB (current)
•	 severe bacterial infections (e.g. pneumonia, empyema, pyomyositis, 
bone or joint infection, meningitis, bacteraemia, severe pelvic 
inflammatory disease)
•	 acute necrotising ulcerative stomatitis, gingivitis or periodontitis
•	 unexplained anaemia (<8 g/dl), neutropaenia (<0.5x109/l) and/or 
chronic thrombocytopenia (<50x109/l).
WHO stage 4 conditions
•	 HIV wasting syndrome 
•	 pneumocystis pneumonia 
•	 recurrent severe bacterial pneumonia 
•	 chronic herpes simplex infection (orolabial, genital or anorectal of 
more than 1 month’s duration or visceral at any site)
•	 oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs)
•	 extrapulmonary TB
•	 Kaposi’s sarcoma
•	 cytomegalovirus infection (retinitis or infection of other organs)
•	 central nervous system toxoplasmosis
•	 HIV encephalopathy
•	 extrapulmonary cryptococcosis including meningitis
•	 disseminated non-tuberculous mycobacteria infection 
•	 progressive multifocal leukoencephalopathy 
•	 chronic cryptosporidiosis
•	 chronic isosporiasis 
•	 disseminated mycosis (extrapulmonary histoplasmosis, 
coccidiomycosis) 
•	 recurrent septicaemia (including non-typhoidal salmonella)
•	 lymphoma (cerebral or B cell non-Hodgkin)
•	 invasive cervical carcinoma 
•	 atypical disseminated leishmaniasis
•	 symptomatic HIV-associated nephropathy
•	 symptomatic HIV-associated cardiomyopathy.








1. Starting ART in hospital
Starting ART in eligible patients in an inpatient setting can be considered 
in certain circumstances, and should be strongly considered during 
prolonged hospitalisation, where adherence, toxicity management and 
other support can be directly provided. However, limited data have 
shown what many experienced clinicians predicted – that patients who 
are initiated on ART within the hospital have high default rates. This 
may be due to several factors – patients who wait to become severely ill 
and enter hospital may still have high levels of denial; they may be too 
ill to take in adherence counselling; and discharge may not be managed 
well. The clinician must carefully weigh up the high risk of deferring 
ART in terms of mortality and morbidity, and the risk for the individual 
patient of default which cannot easily be predicted.
  If a patient is considered for initiation in hospital, the following 
should be attended to:
 
In hospital
•	 Before discharge, the patient must understand the reasons for 
initiation of ART
•	 If the patient is too ill/not mentally competent, a caregiver and/or 
family member who will act as a directly observed therapy supporter 
should be involved




•	 Give very clear ART clinic directions, with a referral letter and details 
of documentation needed by the clinic
•	 Patients should be encouraged to attend the ART clinic as soon as 
possible for an appointment and should be informed of reasonable 
clinic appointment waiting times
•	 Sufficient medication must be provided to last to the ART clinic visit
•	 These patients are often discharged on newly initiated TB treatment; 
few programmes as yet offer integrated TB/ART clinical services, 
and the need for separate clinical visits should be carefully explained
•	 Discharging patients directly into the care of adequately counselled 
family members can be invaluable.
2. High-risk patients
Patients who are at high risk for early mortality, IRIS and ART side-
effects include:
•	 patients with a low BMI, anaemia and low albumin levels
•	 patients with newly diagnosed opportunistic illness, especially TB 
and CM
•	 patients with low CD4 counts.
These patients should be initiated on ART as quickly as possible 
after any underlying opportunistic illnesses have been addressed (note 
the specific guidelines regarding ART timing in TB and CM in the 
guidelines), and should be counselled about the risk of IRIS, which 
may be misinterpreted as ART side-effects. Ideally, patients should 
have access to rapid referral systems, in the events of experiencing 
complicated IRIS or side-effects.
In addition, patients with any of the following are at high risk of 
default or inadequate adherence:
•	 uncontrolled depression
•	 poverty
•	 ambivalence about their HIV status
•	 distrust of the formal health sector
•	 lack of home support or high levels of community stigma
•	 alcohol or other substance abuse
•	 post-partum women.
Adherence issues are addressed in the Southern African Antiretroviral 
Resistance Treatment Guidelines, and include attention to treating 
mental illness and substance use, giving access to support groups, 
addressing potential workplace related issues including drug toxicity 
issues, additional counselling if denial is an issue, honest discussions 
about alternative health providers and churches that may undermine 
adherence, better post-partum integration of women/child HIV services, 
and actively linking poorer patients to poverty alleviation programmes.
3. Common ART misconceptions
•	 You cannot take ART if you do not have food available. None of the 
commonly used first- and second-line options have meaningful food 
restrictions. Patients should be warned that their appetite may return 
and that this may even be uncomfortable. However, food insecurity 
should be managed actively through rapid referral, and this should 
never be a reason to delay ART initiation.
•	 Doses need to be taken at precisely the same time each day. This myth 
was especially prevalent in the earlier days of ART, with anecdotes of 
patients returning to clinic in despair, after having interrupted their 
therapy for several weeks after missing a dose due to oversleeping 
by an hour. Encouraging patients to establish a routine helps with 
adherence, but delayed dosing is rarely a problem, even if out by 
many hours. Most of the drugs have long half-lives, and patients 
should be told simply to take their dose once they remember to do so.
•	 You must never drink alcohol again. Heavy alcohol use may affect 
adherence, and may potentiate the hepatic toxicity of ART and other 
hepatic pathology. However, data do not support the commonly held 
notion that alcohol speeds up the progression to AIDS, nor is there 
any evidence that moderate alcohol use has any negative effect on the 
health of HIV-positive individuals. Local guidelines for the general 
population around responsible alcohol use should be followed; 
prohibition is not advocated.
•	 Disclosure is a prerequisite for ART. This myth probably followed early 
experiences with highly rationed ART, where all possible adherence 
strategies were aggressively pursued to optimise outcomes, and 
bringing in a ‘treatment buddy’ was required to access ART. However, 
it became a form of punishment by some unsophisticated counsellors 
and clinicians, often under the pretext of preventing transmission, 
through making HIV status public. This tactic is almost certainly 
illegal and certainly unethical, and while disclosure may assist 
patients with support and adherence, this should be suggested and 
based on the patient’s individual circumstances. Forced disclosure 
can result in violence at the hands of a partner or community, and 
undermines confidence in confidentiality within the entire health 
system. Patients should be counselled about the pro’s and cons of 
disclosure, and assisted through the process as needed.
•	 Unprotected sex causes virological failure. This myth probably emerges 
from a convoluted understanding of the transmission of resistant 
virus. Theoretically, unprotected sex with someone who is failing 
ART may allow for the passage of resistant virus, but this is unusual. 






Patients should be counselled about safe sex, however, unprotected 
sex itself will not result in virological failure.
4. Adherence interventions
Causes of poor adherence are often complex and linked to social issues. 
Common causes include:
•	 Inadequate treatment literacy. Most HIV programmes have 
extraordinary adherence rates when compared with other chronic 
diseases; this is largely due to effort being made to ensure patients 
understand HIV. If a patient fails therapy, some examination of the 
pre-ART counselling may be merited.
•	 Side-effects. Side-effects are a very common reason for patients to 
default therapy. A careful history of often subtle but distressing 
side-effects (bad dreams, sleepiness, poor concentration, nausea, 
loss of appetite, change of body shape), in conjunction with a work 
history (shift work in particular) may allow for drug substitutions. 
Subtle lipo-atrophy changes from D4T and AZT are often not taken 
seriously by healthcare providers, until disfiguring. Regular enquiry 
and immediate drug substitutions where possible should form part 
of every healthcare worker encounter.
•	 Depression and other mental illnesses. Undiagnosed or under-
treated depression and other mental illness (the frequency of 
major depression is 2 times higher in HIV-positive subjects than 
in matched HIV-negative subjects) may undermine adherence. 
Patients with depression usually respond well to an anti-depressant 
medication in combination with non-pharmaceutical interventions. 
If they do respond it should be given for at least 6 months.
•	 Poverty and food insecurity. Both of these have been related to poor 
adherence and increased missed clinic visits. Patients often lose 
their jobs  due to ill health during the period leading up to ART 
initiation, and should be encouraged to return to the job market as 
soon as feasible or to seek support. This may lead to moving away 
from the ART clinic, and referral must be facilitated. Access to 
available grants, social support and employment non-governmental 
organisations (NGOs) may provide additional support.
•	 Work-related issues. These include shift work and ability to attend 
clinic visits on weekdays. They are a major cause of poor adherence. 
Long clinic waiting times, including monthly pick-ups, may make 
holding down a job untenable, especially with an unsympathetic 
employer. Clinicians should try to encourage clinics to be flexible, 
run smoothly for healthy patients, and provide 3 - 6-monthly 
pharmacy refills.
•	 Substance use. Excessive alcohol use may cause significant problems 
with adherence. In addition, other recreational drugs may cause 
problems in certain parts of the country, and use fluctuates according 
to availability and fad.
•	 Social problems. Stigma and poor social support networks. Perceived 
stigma is correlated with poor adherence; this may manifest in a fear 
of tablets being found, an inability to solicit family or partner support, 
or anxiety regarding an employer, neighbours or a community. Social 
support groups may assist.
•	 Denial. Initiation of ambivalent, conflicted patients on ART is 
unlikely to have a successful outcome. Involvement of family 
members and partners may be an effective mechanism for addressing 
denial.
•	 Pill burden. This is less of an issue than previously, but must 
be considered in patients who are failing treatment. Dosing 
simplification should be a major part of advocacy within public 
sector programmes.
•	 Altered fertility intentions. HIV-discordant or -concordant couples 
may spontaneously decide to cease their ART regimen as they intend 
to begin a family; sympathetic and facilitatory fertility counselling 
during ART initiation counselling, should prevent this.
•	 Conflict of opinions. Conflict of opinions on the use of ARVs occurs 
frequently between healthcare providers, certain alternative health 
providers and churches. This is best addressed with an honest and 
non-judgmental conversation
Practical adherence tools
Tools such as pillboxes, diaries and setting alarms may help patients to 
remember to take their medication. Having an emergency supply of a 
single dose on hand (e.g. in the handbag or workbag) may be useful 
for situations when patients have unexpected delays in getting home. 
Medicine formulations and trade names may change, and patients 
should be educated to recognise the generic name of their current 
regimen to avoid confusion.
